curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has curasan's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: CURK underperformed the German Biotechs industry which returned 1.7% over the past year.
Return vs Market: CURK underperformed the German Market which returned 3.4% over the past year.
Price Volatility Vs. Market
How volatile is curasan's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall Stcurasan AG's (ETR:CURK) Profit Outlook
4 months ago | Simply Wall StIs curasan AG's (ETR:CUR) CEO Overpaid Relative To Its Peers?
5 months ago | Simply Wall StWhat Percentage Of curasan AG (ETR:CUR) Shares Do Insiders Own?
Is curasan undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: CURK (€1.09) is trading below our estimate of fair value (€1.78)
Significantly Undervalued: CURK is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CURK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CURK is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate CURK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CURK is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).
How is curasan forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CURK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CURK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CURK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CURK's revenue (20.4% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: CURK's revenue (20.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: CURK is forecast to be unprofitable in 3 years.
How has curasan performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CURK is unprofitable, and losses have increased over the past 5 years at a rate of -37.9% per year.
Accelerating Growth: Unable to compare CURK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: CURK has a negative Return on Equity (-101.84%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: CURK is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: CURK is currently unprofitable, so its Return on Capital Employed is negative.
How is curasan's financial position?
Financial Position Analysis
Short Term Liabilities: CURK's short term assets (€4.6M) exceeds its short term liabilities (€4.0M)
Long Term Liabilities: CURK's short term assets (4.6M) exceeds its long term liabilities (571.0K)
Debt to Equity History and Analysis
Debt Level: CURK's debt to equity ratio (37.7%) is considered satisfactory
Reducing Debt: CURK's debt to equity ratio has increased from 2.8% to 37.7% over the past 5 years.
Inventory Level: CURK has a high level of physical assets or inventory.
Debt Coverage by Assets: CURK's debt is covered by short term assets (assets are 2.157370x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CURK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CURK has less than a year of cash runway if free cash flow continues to reduce at historical rates of -52.2% each year
What is curasan's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate CURK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CURK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CURK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CURK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CURK is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CURK's dividend in 3 years as they are not forecast to pay a notable one for the German market.
What is the CEO of curasan's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Torben Sorensen 0
Mr. Torben Sorensen serves as Chief Executive Officer at curasan AG since September 16, 2019. He has been a successful, internationally active interim manager and has reputation as a turnaround specialist ...
Management Age and Tenure
Experienced Management: CURK's management team is considered experienced (3.4 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Fabian Peters (49yo)
- Tenure: 0yrs
Head of Investor Relations
- Tenure: 0yrs
Head of Marketing & Sales
- Tenure: 4.5yrs
Head of Corporate Communications
- Tenure: 0yrs
President of USA
- Tenure: 3.4yrs
Chief Executive Officer
- Tenure: 0.08yrs
Chairman of the Supervisory Board
- Tenure: 0yrs
- Compensation: €28.00k
Kurt Berger (53yo)
Member of Supervisory Board
- Tenure: 0.08yrs
Isabella de Krassny (61yo)
Deputy Chairman of the Supervisory Board
- Tenure: 0yrs
curasan AG's company bio, employee growth, exchange listings and data sources
- Name: curasan AG
- Ticker: CURK
- Exchange: XTRA
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €9.882m
- Shares outstanding: 9.07m
- Website: https://www.curasan.de
Number of Employees
- curasan AG
- Lindigstrasse 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CURK||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Jul 2000|
|CURK||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Jul 2000|
curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company specializes in offering biomimetic bone ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/17 20:57|
|End of Day Share Price||2019/10/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.